Independent Researcher Case Studies
Observational data from independent harm reduction research.
The following data is compiled from independent investigative reports and case studies. It is intended for analytical purposes to understand how SR-17018 interacts across varying opioid tolerance levels.
🧪Key Observations
- Fentanyl (600 mg/day):
80 mg twice daily for one week, followed by 80 mg once daily, showed significant reduction in withdrawal symptoms. - Morphine (1–50 mg IV/day):
250 mg initial dose stabilized the subject, followed by tapering to 25 mg daily without withdrawal. - Etonitazepyne (1 g/day):
300 mg per day (divided doses) tapered to zero over 17 days. - Methadone (100 mg/day):
18–100 mg twice daily managed withdrawal symptoms during early transition. - Suboxone (4 mg/day):
25 mg starting dose sufficient for transition studies. - Kratom (300 mg/day):
65 mg every 8 hours stabilized symptoms effectively. - ODSMT (180 mg – 1 g/day):
50 mg every 12 hours to 80–140 mg three times daily required for maintenance.
📊 Independent Researcher Experience Reports
| Research Class | Baseline Profile | Investigative Protocol | Key Observations |
|---|---|---|---|
| High-Potency Synthetics | 1–50 mg IV Cychlorphine | 250 mg initial sample | Withdrawal markers neutralized. |
| Nitazene Derivatives | 1 g/day Etonitazepyne | 300 mg/day (divided) | Effective stabilization reported. |
| Methadone (Jump-Off) | 100 mg/day Maintenance | 100 mg 2x daily; 13-day taper | Displacement without acute agony. |
| Botanical Extracts | 300 mg Mitragynine/day | 65 mg every 8 hours | 2/3 reduction in tolerance observed. |
| Suboxone Research | Chronic maintenance | 100 mg/day for 14 days | Successful cessation. |
SR-17018 significantly reduces opioid tolerance. If a research subject resumes use of their previous compound (e.g., Fentanyl, Heroin, Zenes) at their prior "maintenance" dose, the risk of FATAL OVERDOSE is extreme because the body can no longer handle that amount.
Summary of Research Findings
Research Parameter
Observed Result
Tolerance Reset
Significant reduction within 4–12 days
Withdrawal Relief
No Euphoric Potential Relieve Hot/Cold Sweats, Stomach Cramps, Body Aches, Insomnia, Restless Legs, Some Cravings
Cravings Management
Suppressed during use; mild return after cessation
Safety & Research Alerts
Tolerance Warning
SR-17018 significantly reduces opioid tolerance. Returning to previous substances at prior doses may result in a high risk of fatal overdose.
Research Notice
All data is based on independent observational reports and is intended for analytical purposes only.
Critical Risk
Resuming compounds such as fentanyl, heroin, or similar substances at previous maintenance levels may exceed the body’s reduced tolerance capacity and lead to severe consequences.